Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of the tumor immune-microenvironment of adenocarcinoma of lung with a metastatic lesion in the pancreas treated successfully with first-line, single-agent pembrolizumab.
Saltman DL, Nielsen TJ, Salina D, Hout DR, McMahon FB, Valev BR, Huk M, Chandra PK, Spille J, Seitz RS, Schweitzer BL. Saltman DL, et al. Among authors: seitz rs. Ther Adv Med Oncol. 2021 Apr 19;13:17588359211010156. doi: 10.1177/17588359211010156. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33953802 Free PMC article.
Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research.
Espinosa Fernandez JR, Eckhardt BL, Lee J, Lim B, Pearson T, Seitz RS, Hout DR, Schweitzer BL, Nielsen TJ, Lawrence OR, Wang Y, Rao A, Ueno NT. Espinosa Fernandez JR, et al. Among authors: seitz rs. PLoS One. 2020 Apr 30;15(4):e0231953. doi: 10.1371/journal.pone.0231953. eCollection 2020. PLoS One. 2020. PMID: 32353087 Free PMC article.
Clinical Activity of Pembrolizumab in a Patient With Metastatic Triple-Negative Breast Cancer Without Tumor Programmed Death-Ligand 1 Expression: A Case Report and Correlative Biomarker Analysis.
Bhatti S, Heldstab J, Lehn C, Tawfik O, Ash RM, Hout DR, Seitz RS, Bailey DB, O'Dea AP, Jensen RA, Fan F, Khan QJ, Godwin AK, Sharma P. Bhatti S, et al. Among authors: seitz rs. JCO Precis Oncol. 2017 Nov;1:1-6. doi: 10.1200/PO.17.00032. JCO Precis Oncol. 2017. PMID: 35172501 No abstract available.
Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy.
Masuda H, Harano K, Miura S, Wang Y, Hirota Y, Harada O, Jolly MK, Matsunaga Y, Lim B, Wood AL, Parinyanitikul N, Jin Lee H, Gong G, George JT, Levine H, Lee J, Wang X, Lucci A, Rao A, Schweitzer BL, Lawrence OR, Seitz RS, Morris SW, Hout DR, Nakamura S, Krishnamurthy S, Ueno NT. Masuda H, et al. Among authors: seitz rs. JCO Precis Oncol. 2022 Mar;6:e2000368. doi: 10.1200/PO.20.00368. JCO Precis Oncol. 2022. PMID: 35294223 Free PMC article.
Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Ranganath H, Jain AL, Smith JR, Ryder J, Chaudry A, Miller E, Hare F, Valasareddy P, Seitz RS, Hout DR, Varga MG, Schweitzer BL, Nielsen TJ, Mullins J, Ross DT, Gandara DR, Vidal GA. Ranganath H, et al. Among authors: seitz rs. BMC Cancer. 2022 Apr 14;22(1):407. doi: 10.1186/s12885-022-09470-y. BMC Cancer. 2022. PMID: 35421940 Free PMC article.
44 results